Here is what went into this page specifically: I pulled the full text of the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine on May 11, 2025 (DOI: 10.1056/NEJMoa2416394) and cross-referenced it with the Phase 3 TRIUMPH-4 topline readout from Eli Lilly on December 11, 2025
Healthcare providers can perform targeted assessment including thyroid function tests, cardiovascular evaluation, and review of concurrent medications that might contribute to vasomotor symptoms
MTHFR, MTR, MTRR, CBS and COMT
However, subsequent clinical trials failed to validate these findings
Creatine: A study published in the Journal of the International Society of Sports Nutrition (JISSN) recommends drinking an additional 1.5 to 2 liters of water per day when supplementing with creatine
GLP-1 is a hormone released from the gut after meals that: Stimulates insulin release when blood sugar is high Reduces glucagon levels Slows stomach emptying Signals satiety to the brain Modern GLP-1based medications (semaglutide alone and tirzepatide as a dual GIP/GLP-1 agonist) mimic or combine these effects